^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    radgocitabine (DFP-10917)

    i
    Other names: DFP-10917, DFP10917, NS 917, TAS-109, CNDAC, DFP 10917, NS917, NS-917, TAS109, TAS 109
    Associations

    News

    Trials
    Company:
    Delta-Fly Pharma, Nippon Shinyaku
    Drug class:
    DNA-directed DNAP inhibitor, G2 checkpoint inhibitor
    Related drugs:
    Associations

    News

    Trials
    3ms
    DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=39, Recruiting, Delta-Fly Pharma, Inc. | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Mar 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • radgocitabine (DFP-10917)
    9ms
    Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (clinicaltrials.gov)
    P3, N=450, Recruiting, Delta-Fly Pharma, Inc. | Trial primary completion date: Dec 2022 --> Dec 2025 | Trial completion date: Dec 2022 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • decitabine • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • radgocitabine (DFP-10917)
    over1year
    DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=39, Recruiting, Delta-Fly Pharma, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • radgocitabine (DFP-10917)
    over1year
    Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=39, Not yet recruiting, Delta-Fly Pharma, Inc.
    New P1/2 trial • Combination therapy
    |
    Venclexta (venetoclax) • radgocitabine (DFP-10917)
    over2years
    A polyethylene glycol-conjugate of deoxycytidine analog, DFP-14927, produces potential antitumor effects on pancreatic tumor-xenograft murine models via inducing G2/M arrest. (PubMed, Eur J Pharmacol)
    These effects were comparable to that of free DFP-10917 as well as to that of gemcitabine, which is considered a standard in the treatment of pancreatic cancer. Intravenous administration of the newly synthesized DFP-14927 has induced G2/M arrest in human pancreatic tumor-xenograft murine models, which represents an improvement in the pharmacokinetics of DFP-10917. DFP-14927 could be an alternative for patients who cannot accept prolonged or continuous infusions of DFP-10917.
    Preclinical • Journal
    |
    gemcitabine • radgocitabine (DFP-10917)